<?xml version="1.0" encoding="UTF-8"?>
<p> The prospect of using a serologic assay to directly measure (or estimate) HIV incidence from cross-sectional specimen collection first showed promise using a somewhat primitive modified ELISA in 1998 (Janssen 
 <italic>et al.</italic>, 1998 
 <sup>
  <xref rid="rep-ref-27584-2" ref-type="bibr">2</xref>
 </sup>). Subsequent assays were developed to address the shortcomings identified with each later iteration of assays (Busch 
 <italic>et al.</italic>, 2010 
 <sup>
  <xref rid="rep-ref-27584-3" ref-type="bibr">3</xref>
 </sup>), but, as specified in several of the authors’ citations, no single assay method can precisely estimate incidence; WHO guidance stipulates that assay-based estimation is not absolute (World Health Organization, 2018 
 <sup>
  <xref rid="rep-ref-27584-4" ref-type="bibr">4</xref>
 </sup>); and other studies by these same authors demonstrate that assay-based incidence estimates with the same specimens differ depending on the assay, specimen type, and context (Schlusser 
 <italic>et al.</italic>, 2017 
 <sup>
  <xref rid="rep-ref-27584-5" ref-type="bibr">5</xref>
 </sup> and Sempa 
 <italic>et al.</italic>, 2019 
 <sup>
  <xref rid="rep-ref-27584-6" ref-type="bibr">6</xref>
 </sup>). These cause me concern about the implications of the recent proposed deployment of the rapid POC “recency” assay (authors’ citation 46) reminiscent of the premature distribution of the BED assay.  
 <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/233008/WER8104_40-40.PDF?sequence=1&amp;isAllowed=y" xmlns:xlink="http://www.w3.org/1999/xlink">https://apps.who.int/iris/bitstream/handle/10665/233008/WER8104_40-40.PDF?sequence=1&amp;isAllowed=y</ext-link>.
</p>
